The Trial Is Run by a Company Whose Name Is Not on the Drug
Pharmaceutical companies outsource most clinical trial execution to contract research organisations. The arrangement converts an enormous fixed cost into a variable one and moves operational knowledge outside the sponsor.
Why the Work Got Outsourced
Running a clinical trial requires selecting and contracting investigational sites, obtaining ethics approvals across jurisdictions, recruiting patients, monitoring sites for protocol compliance, collecting and cleaning data, managing safety reporting, and preparing submissions.
The workload is enormous, highly specialised, and extremely uneven. A pharmaceutical company running four trials this year and eleven next year cannot hold the staff for the peak.
A contract research organisation solves that by holding the specialist capability and spreading it across many sponsors, converting a fixed cost into a variable one for each customer.
What They Actually Do
| Activity | Typically Performed By |
|---|---|
| Deciding what to develop | Sponsor |
| Designing the trial protocol | Sponsor, sometimes with CRO input |
| Site selection and contracting | CRO |
| Patient recruitment | CRO and sites |
| Monitoring and data management | CRO |
| Regulatory submission preparation | CRO or sponsor |
| Owning the result | Sponsor |
The division reflects a clean principle. The sponsor keeps the scientific and commercial decisions and the intellectual property. The CRO executes.
Outsourcing execution while retaining the science is coherent. The consequence, accumulated over two decades, is that the operational expertise in running trials now sits substantially outside the companies that own the drugs.
The Business Model
Contracts are typically priced per unit of work: per site activated, per patient enrolled, per monitoring visit, per data point cleaned, with a management fee.
That structure means the CRO revenue depends on trial activity actually occurring, and the recurring commercial problem is that trials are delayed. A contract signed does not become revenue until sites open and patients enrol.
The industry therefore reports backlog and a book to bill ratio, comparing new awards against revenue recognised. Those are the primary indicators an analyst watches, and the gap between backlog and revenue conversion is where the operational risk sits.
Cancellations are a permanent feature, since a sponsor that discontinues a programme after an interim analysis cancels the trial and the associated backlog disappears.
The Recruitment Problem
The single largest cause of trial delay is patient enrolment, and it is the area where CROs compete most directly.
Trials increasingly require patients meeting narrow criteria, frequently defined by genetic markers, which means the eligible population at any single site is small. Finding them requires screening large numbers, and screen failure rates in some therapeutic areas are very high.
The responses have included using electronic health record data to identify eligible patients before a site is selected, decentralised trial designs allowing participation from home with remote monitoring, and expanding into geographies with larger treatment naive populations.
That last approach raises its own questions about whether trial populations resemble the populations that will eventually receive the drug, which is a scientific concern as well as an ethical one.
The Consolidation
The industry consolidated substantially, driven by two forces.
Sponsors moved from awarding individual trials to awarding strategic partnerships, giving a small number of preferred CROs a large share of their pipeline. Winning those relationships requires global capability across every therapeutic area, which favours scale.
And several large CROs merged with clinical data and analytics businesses, on the reasoning that access to real world health data improves site selection and patient identification, which is the binding constraint.
The result is a market where a handful of very large organisations handle the majority of outsourced spend, and sponsors have correspondingly less negotiating leverage than the fragmented market once offered.
The Conflict Question
An organisation paid by the sponsor of a trial to conduct that trial has an obvious structural tension, and it is managed rather than eliminated.
The protections are that the CRO does not analyse the primary endpoint independently in most designs, that data safety monitoring boards operate independently of both parties, that regulators inspect trial conduct directly, and that the sponsor bears the ultimate regulatory liability for the data.
Enforcement actions concerning trial conduct have generally involved site level misconduct rather than CRO level manipulation, which suggests the controls function reasonably. The structural point remains that the party executing the trial is paid by the party that wants a positive result.
How to Read the Sector
The useful indicators are book to bill and the trend in it, cancellation rates, backlog conversion speed, and customer concentration, since a CRO deriving a large share of revenue from a few sponsors is exposed to those sponsors pipeline decisions.
The sector is also a leading indicator for pharmaceutical research spending generally, since awards are made before trials start and reflect sponsor commitment decisions taken earlier.
The Bottom Line
Contract research organisations exist because clinical trial workload is enormous, specialised, and lumpy, and outsourcing converts it into a variable cost for sponsors who could never staff for their own peaks. The economics run on utilisation and on converting backlog into revenue, and the binding operational constraint is patient recruitment rather than anything the CRO controls directly. Two decades of outsourcing have moved the operational expertise in running trials outside the companies that own the medicines, which is efficient and is also a dependency that is now difficult to reverse.